ArticleWorld journal of surgical oncology2026
Machine learning-based prognostic model integrating preoperative HALP score and lactate dehydrogenase for predicting postoperative recurrence of prostate cancer.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivePostoperative biochemical recurrence (BCR) of prostate cancer (PCa) remains a major clinical challenge, and traditional risk assessment systems show suboptimal predictive performance for PCa recurrence. This study aimed to develop and validate interpretable machine learning (ML) models for predicting PCa postoperative recurrence by integrating multi-dimensional clinical features, and to construct a simplified and practical prognostic model for individualized risk stratification.
methodsA total of 320 PCa patients (125 recurrences vs. 195 non-recurrences) who underwent laparoscopic radical prostatectomy (LRP) at the primary center were retrospectively enrolled as the internal cohort, and 144 patients (50 recurrences vs. 94 non-recurrences) from another campus were included as the external validation cohort. Ten ML algorithms were used to construct prediction models with clinicopathological, preoperative hematological and nutrition-inflammation features. Stratified sampling and ten-fold cross-validation were used for model training and validation, and SHAP analysis was adopted for feature importance evaluation and model interpretability. Recursive feature inclusion was performed to optimize the model, and clinical cutoffs of key indicators were determined.
resultsThe gradient boosting machine (GBM) model achieved the best predictive performance in the internal cohort with an AUC of 0.891, which was significantly superior to the UCSF-CAPRA score (AUC = 0.703) and the D'Amico classification (AUC = 0.610). A simplified 5-feature GBM model [positive surgical margin, preoperative hemoglobin-albumin-lymphocyte-platelet (HALP) score, postoperative Gleason score, preoperative maximum prostate specific antigen, preoperative lactate dehydrogenase (LDH)] achieved an AUC of 0.912 in the internal cohort and 0.895 in the external cohort, with excellent calibration and higher net clinical benefit. The optimal cutoffs were 41.31 for preoperative HALP score and 182.61 U/L for preoperative LDH. Low HALP was associated with shorter recurrence-free survival (HR = 0.30, P < 0.0001), and high LDH indicated increased recurrence risk (HR = 1.37, P = 0.083). A three-tier risk stratification system was established based on the cutoff values to predict postoperative recurrence risk.
conclusionThe ML model integrating preoperative HALP score, LDH and core clinicopathological features has high accuracy and good clinical applicability for predicting PCa postoperative recurrence. Validated successfully in both internal and external cohorts, the 5-feature simplified model can serve as a practical tool for individualized recurrence risk assessment, facilitating optimized clinical management of PCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.